Q2Earth, Inc. Appoints David Shields as Chief Financial Officer
August 07, 2018 at 02:44 am IST
Share
On August 1, 2018, Q2Earth, Inc. announced the appointment of David Shields as Chief Financial Officer of the company. Prior to joining the company, he served as the Vice President of Corporate Development for Oldcastle BuildingEnvelope®, a division of CRH plc and the fabricator and distributor of commercial glass, engineered products, and glazing hardware and supplies in North America. During his three-year tenure at Oldcastle, he was responsible for overall strategy development, sourcing acquisition opportunities and conducting due diligence, valuation, and contract negotiation for multiple acquisitions, divestitures and capital expenditure projects encompassing greater than $1 billion. Prior to Oldcastle, he gained significant experience in the organics sector as the Managing Director of Corporate Development for BCR Environmental Corporation. Prior to BCR over a six-year period of time, he was an investment banker with Wells Fargo Securities, UBS Securities and Morgan Keegan and Company where he provided strategic financial advice and transaction execution expertise to companies in a variety of industries.
QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Companyâs technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group, LLC. Iso Therapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 with a chelating agent, DOTMP (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylenephosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to take images of the skeleton and locate and characterize the size and nature of tumors.
QSAM BIOSCIENCES, INC. 
